Predictors for successful treatment outcome in patients with comorbid attention-deficit/hyperactivity disorder (ADHD) and substance use disorder (SUD): an international observational cohort study

Conditions

Attention deficit hyperactivity/impulsivity disorder with comorbid substance use disorder Mental and Behavioural Disorders

Christoffer Brynte, Arnt Schellekens, Csaba Barta, Alex Begeman, Cleo L. Crunelle et al. (26 authors)

The Journal of Clinical Psychiatry2024-12-231 citations

10.4088/jcp.24m15494

The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study.

Brynte C, Aeschlimann M, Barta C, Begeman AHA, Bäcker A, Crunelle CL, Daigre C, De Fuentes-Merillas L, Demetrovics Z, Dom G, López LG, Icick R, Johnson B, Joostens P, Kapitány-Fövény M, Karsinti E, Kiefer F, Konstenius M, Levin FR, Luderer M, Markus W, Matthys F, Moggi F, Palma-Alvarez RF, Paraskevopoulou M, Ramos-Quiroga JA, Schellekens A, Soravia LM, Therribout N, Thomas A, van de Glind G, van Kernebeek MW, Vollstädt-Klein S, Vorspan F, van den Brink W, Franck J.

2022-09-239 citations

10.1186/s12888-022-04259-6

Interventions

This study is non-interventional and investigates the treatment modalities provided to the study population at the participating treatment services. This study will invite 600 treatment-seeking patie

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Men and women =18 years of age seeking treatment for SUD at any of the participating sites 2. ADHD diagnosis according to DSM-5 3. SUD diagnosis (DSM-5 moderate to severe, ICD-10 dependence)

Exclusion criteria

Exclusion criteria: There are no formal exclusion criteria except incapability to complete the assessments

Design outcomes

Primary

Measure	Time frame
1. Retention to treatment, defined as time to drop-out (last contact between patient and treatment center) 2. ADHD symptoms measured using the Adult ADHD Self-Report Scale (ASRS) at 3 months follow-up 3. Number of days with heavy alcohol use or days with illicit drug use during the last 30 days, measured using the Time-Line Follow-Back instrument at 3 months follow-up	—

Secondary

Measure	Time frame
1. ADHD symptoms measured using the adult ASRS at 9 months follow-up 2. Substance use measured with TLFB, defined as the number of days with heavy alcohol use or days with illicit drug use the last 30 days at 9 months follow-up. 3. ADHD symptoms according to the Expanded Adult ADHD Self-Report Scale at 3 and 9 months follow-up, respectively 4. Employment measured using questionnaire and patient files at baseline, 3 months and 9 months 5. Number of accidents as reported by the participant using questionnaire and patient files at baseline, 3 months and 9 months 6. Days with any alcohol use during the last 30 days measured using Timeline Follow-Back interview at baseline, 3 months and 9 months follow-up	—

Measure

Time frame

1. ADHD symptoms measured using the adult ASRS at 9 months follow-up 2. Substance use measured with TLFB, defined as the number of days with heavy alcohol use or days with illicit drug use the last 30 days at 9 months follow-up. 3. ADHD symptoms according to the Expanded Adult ADHD Self-Report Scale at 3 and 9 months follow-up, respectively 4. Employment measured using questionnaire and patient files at baseline, 3 months and 9 months 5. Number of accidents as reported by the participant using questionnaire and patient files at baseline, 3 months and 9 months 6. Days with any alcohol use during the last 30 days measured using Timeline Follow-Back interview at baseline, 3 months and 9 months follow-up

—

Countries

Australia, Belgium, France, Germany, Hungary, Netherlands, Spain, Sweden, Switzerland, United States of America

Outcome results

None listed